Douglas Crawford
General Manager & Founder @ MBC BioLabs
San Francisco, United States
Douglas Crawford is a Series A investor at MBC BioLabs in San Francisco focused on Health Care and Medical Device. Douglas Crawford’s goal is to help stimulate economic growth in California by promoting cross-discipline academic research and accelerating the transfer of the resulting innovations to the market. Crawford created and manages the first incubator within the University of California, the QB3 Garage@UCSF, which has now expanded to include the QB3Garage@Berkeley, the QB3 Mission Bay Innovation Center, and the QB3 East Bay Innovation Center. Together these incubators are currently home to 42 companies. Crawford is also a founder and managing director of Mission Bay Capital, an $11.3M seed-stage venture fund that seeks to make pivotal early-stage investments in bioscience companies emerging from UC. He is a board member of Redwood Biosciences (observer), Delpor, and the BayBio Institute. Crawford received his PhD in biochemistry from UCSF.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Douglas Crawford invests in
Stages Douglas Crawford invests in
Countries Douglas Crawford invests in
Investment Focus
Industry
- Health Care 1 (100%)
- Medical Device 1 (100%)
- Nanotechnology 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
GraphWear Technologies
|
GraphWear is reinventing the way we map human health. Pioneering a no-needle, no-blood approach to disease monitoring, GraphWear’s technology offers the first genuinely non-invasive method to map patient health, unlocking a new adherence for some of the most significant chronic diseases. By empowering access to accurate and timely healthinformation in an easy-to-use format, GraphWear aims to drive greater efficiency across diagnosis, management, and care. GraphWear is currently in clinical trials for its first target, monitoring glucose levels for diabetes, with additional potential across conditions like heart disease and cancer. | $4.2M / Series A / Apr 17, 2018 |
Co-Investors
About MBC BioLabs
MBC BioLabs is the premier biotech incubator in the Bay Area and we lower the barriers to entry, minimize the start-up hurdles and provide a launchpad to take theories from hypothesis to data. With state-of-the-art equipment, a vibrant community, and a la carte business services, we enable and empower entrepreneurial scientists to run their labfast, frugal, and focused.
MBC BioLabs Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Douglas Crawford
General Manager & Founder
|
|||
4 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Douglas Crawford invest in?
Douglas Crawford invests primarily in Health Care, Medical Device and Nanotechnology startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Douglas Crawford last invest?
The most recent investment recorded for Douglas Crawford closed in Apr 2018. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
